BioNTech, OncoC4 collaborate on novel CTLA-4 antibody therapy
The collaboration aims to develop and market OncoC4’s monoclonal antibody candidate, ONC-392, as a standalone, or combination therapy…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Mar 23
The collaboration aims to develop and market OncoC4’s monoclonal antibody candidate, ONC-392, as a standalone, or combination therapy…
21 Mar 23
Designated as GS-6791, NX‑0479 is a bivalent degrader which is the first development candidate resulting from the previously…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Mar 23
“I am honoured to join the Mölnlycke Board and collaborate with the team to advance medical products and…
20 Mar 23
"It is our commitment to unwavering integrity that makes it possible to receive this recognition as one of…
20 Mar 23
The contract development and manufacturing organisation (CDMO) intends to build Plant 5 at Bio Campus II, with a…
20 Mar 23
Droplet’s foundational breakthrough is a non-invasive process to access lymph through the collection of surgical drain fluid after…
20 Mar 23
Active wound care involves a variety of treatments depending on the type and severity of the wound
20 Mar 23
Accounting for less than 2% of its total global workforce of over 25,000, the latest move is Amgen’s…
17 Mar 23
The FDA approval is based on results from the Phase 2/3 TADPOLE clinical trial, in which the combination…
17 Mar 23
The dermatology brands sold by Dr. Reddy's to Eris Lifesciences include Hydroheal, Revilus, Avarta, Aquaderm, and others